Shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) have earned a consensus rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $21.75.
Several research analysts have issued reports on the company. WBB Securities cut RedHill Biopharma from a “strong-buy” rating to a “buy” rating and dropped their target price for the stock from $17.00 to $16.00 in a research report on Friday, May 28th. Roth Capital reissued a “buy” rating on shares of RedHill Biopharma in a research report on Tuesday, June 1st. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of RedHill Biopharma in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $26.00 price objective on shares of RedHill Biopharma in a research report on Monday, May 31st. Finally, Zacks Investment Research raised RedHill Biopharma from a “strong sell” rating to a “hold” rating in a research report on Wednesday.
A number of hedge funds and other institutional investors have recently bought and sold shares of RDHL. Bank of Montreal Can lifted its holdings in RedHill Biopharma by 626.7% in the 1st quarter. Bank of Montreal Can now owns 4,549 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,923 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in RedHill Biopharma in the 4th quarter worth approximately $40,000. Cubist Systematic Strategies LLC bought a new stake in RedHill Biopharma in the 1st quarter worth approximately $98,000. HRT Financial LP bought a new stake in RedHill Biopharma in the 1st quarter worth approximately $118,000. Finally, Squarepoint Ops LLC bought a new stake in RedHill Biopharma in the 1st quarter worth approximately $136,000. 22.82% of the stock is currently owned by institutional investors.
RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Wednesday, May 26th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.29. The company had revenue of $20.58 million during the quarter, compared to the consensus estimate of $22.37 million. RedHill Biopharma had a negative return on equity of 251.48% and a negative net margin of 97.62%. On average, equities analysts predict that RedHill Biopharma will post -1.48 earnings per share for the current fiscal year.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.